SCHEMBL6931003

SCHEMBL6931003

O=c1ccc(CBr)c[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1161509 0.98 ALDH1A1 (0.48)
SCHEMBL17241205 0.87 ALDH1A1 (0.43)
SCHEMBL18616803 0.76
SCHEMBL1160586 0.76
Bromide SCHEMBL23375434 0.74 ALDH1A1 (0.43)
Hydrochloric Acid SCHEMBL31738473 0.74 ALDH1A1 (0.43)
SCHEMBL21459324 0.74 ALDH1A1 (0.43)
SCHEMBL28815221 0.73 ALDH1A1 (0.41)
SCHEMBL12844536 0.73 GPR84 (0.42)
SCHEMBL7238341 0.73 HRH3 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001594-B2 Heterocyclic modulators of HIF activity for treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-05-11 US disclosed
CN-111556867-A Substituted pyrrolidine amides I 格吕伦塔尔有限公司 2020-08-18 CN disclosed
US-20190270753-A1 HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE UNIV TEXAS (US) 2019-09-05 US disclosed
US-10208059-B2 Heterocyclic modulators of HIF activity for treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-02-19 US disclosed
EP-2888255-B1 HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE UNIV TEXAS (US) 2018-07-18 EP disclosed
US-20170121342-A1 HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM 2017-05-04 US disclosed
EP-2888255-A2 HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE Board of Regents, The University of Texas System (US) 2015-07-01 EP disclosed
US-9018380-B2 Heterocyclic modulators of HIF activity for treatment of disease Boar of Regents, The University of Texas System (US) 2015-04-28 US disclosed
US-20140066424-A1 HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) 2014-03-06 US disclosed
WO-2014031936-A2 HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE JONES PHILIP (US) 2014-02-27 WO disclosed
WO-2011012622-A1 BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2011-02-03 WO disclosed
US-6544986-B2 Such as 5-(N,N-dibenzyl)aminocarbonyl-2-pyridone; enzyme inhibitors; for treatment of Alzheimer's disease DALHOUSIE UNIVERSITY (CA) 2003-04-08 US disclosed
US-6436972-B1 HETEROCYCLIC AMIDES, USED AS ANTICHOLINERGICS AND SERINE PROTEASE STIMULANTS, FOR PROPHYLAXIS OF ALZHEIMER'S DISEASE, GLIOMAS AND VISION DEFECTS DALHOUSIE UNIVERSITY (CA) 2002-08-20 US disclosed
US-20020049330-A1 Novel pyridones and their use as modulators of serine hydrolase enzymes DALHOUSIE UNIVERSITY 2002-04-25 US disclosed
WO-2001077078-A1 NOVEL PYRIDONES AND THEIR USE AS MODULATORS OF SERINE HYDROLASE ENZYMES DALHOUSIE UNIVERSITY (CA) 2001-10-18 WO disclosed
US-5264437-A Antiinflammatory agents, immunosuppressants or antiallergens SYNTEX (U.S.A.) INC. (US) 1993-11-23 US disclosed